Real-world evidence demonstrated that the characteristics of patients with metastatic colorectal cancer who received bevacizumab-awwb in the first year after product launch were similar regardless of prior bevacizumab use, and that bevacizumab-awwb was used in new and continuing patients.
The biosimilar bevacizumab-awwb was approved based on phase 3 clinical trial evidence in nonsquamous non–small-cell lung cancer. A retrospective, observational study evaluated clinical use of bevacizumab-awwb in metastatic colorectal cancer (mCRC) and described the demographic and clinical characteristics of these patients; the results of this study were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
A review of medical records from the ConcertAI Definitive Oncology Dataset identified patients who were aged ≥18 years and were diagnosed with mCRC, who initiated bevacizumab-awwb as first- or later-line treatment. In the analysis, patients were stratified by prior bevacizumab use.
A total of 304 patients were identified and included in the study. In mCRC, the first use of bevacizumab-awwb occurred within 20 days of product launch. Of all eligible patients (n = 304), the majority (86%) were treated in a community setting and 53% received prior bevacizumab. The majority (83%) of patients with prior bevacizumab use (n = 162) had no disease progression between the last bevacizumab infusion and start of bevacizumab-awwb. Among patients who received a biosimilar after prior bevacizumab use, the majority (83%) received bevacizumab-awwb within 28 days of the last bevacizumab dose without evidence of progression, indicating that treatment change occurred within the same line of therapy.
When stratified by prior bevacizumab use, the demographic and clinical characteristics of patients treated first-line with a biosimilar were comparable with those who had received prior bevacizumab. The majority of patients had a histological diagnosis of adenocarcinoma with primary tumors in the rectum or sigmoid colon. Overall, the most common comorbidities were diabetes (24%), chronic obstructive pulmonary disease (10%), and renal disease (8%).
Based on these real-world data, it was concluded that the characteristics of patients with mCRC who received bevacizumab-awwb in the first year after product launch were similar regardless of prior bevacizumab use, and that bevacizumab-awwb was used in new and continuing patients, indicating that physicians were comfortable using the biosimilar.
Source: DeClue R, Rhodes W, Accortt NA, et al. Demographics and clinical characteristics of metastatic colorectal cancer patients treated with bevacizumab-awwb in real-world oncology clinics. J Clin Oncol. 2021;39(suppl_3):90.
